FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3132348878> ?p ?o ?g. }

• W3132348878 endingPage "102843" @default.
• W3132348878 startingPage "102843" @default.
• W3132348878 abstract "•Neuromyelitis optica is a serious autoimmune disease of the central nervous system. •The incidence of the disease in females is significantly higher than that in males. •Rituximab can effectively treat the disease (reduce the annual recurrence rate) •Rituximab can improve the degree of disability in patients with neuromyelitis optica. Background Neuromyelitis optica spectrum disorders (NMOSD) is an autoimmune astrocyte disease that mainly affects the optic nerve and spinal cord resulting in blindness or paralysis. Rituximab (RTX) is a chimeric monoclonal antibody directed against the surface antigen of CD20 on B lymphocytes and is an emerging treatment option in NMOSD. The present review aimed to conduct an update systematic review and meta-analysis for the efficacy of RTX in the treatment of NMOSD and analyze main factors affecting the efficacy of RTX. Methods The following Medical Subject Heading (MeSH) and related entry terms are used to search English literature in PubMed, MEDLINE and CENTRAL databases, respectively. MeSH include: Neuromyelitis optic and Rituximab; entry terms include: NMO Spectrum Disorder, NMO Spectrum Disorders, Neuromyelitis Optica (NMO) Spectrum Disorder, Neuromyelitis Optica Spectrum Disorders, Devic Neuromyelitis Optica, Neuromyelitis Optica, Devic, Devic's Disease, Devic Syndrome, Devic's Neuromyelitis Optica, Neuromyelitis Optica (NMO) Spectrum Disorders, CD20 Antibody, Rituximab CD20 Antibody, Mabthera, IDEC-C2B8 Antibody, GP2013, Rituxan; (note: literature retrieval operators “AND” “OR” “NOT” are used to link MeSH with Entry Terms.) 54 studies were included in this systematic review and 29 studies were included in meta-analysis. The main efficacy indicators were the difference of the expanded disability status scale (EDSS) and annualized relapse rate (ARR) between before and after rituximab treatments. Results In 29 studies involving 732 patients (643 women, 84 men, 5 with unknown gender), the EDSS and ARR were reduced by an average of −0.57 (95%CI, −0.69 to −0.44), −1.57 (95%CI, −1.78 to −1.35), respectively. Conclusion Our systematic review and update meta-analysis provide new evidences that RTX can effectively improve disability and reduce ARR ratio. Neuromyelitis optica spectrum disorders (NMOSD) is an autoimmune astrocyte disease that mainly affects the optic nerve and spinal cord resulting in blindness or paralysis. Rituximab (RTX) is a chimeric monoclonal antibody directed against the surface antigen of CD20 on B lymphocytes and is an emerging treatment option in NMOSD. The present review aimed to conduct an update systematic review and meta-analysis for the efficacy of RTX in the treatment of NMOSD and analyze main factors affecting the efficacy of RTX. The following Medical Subject Heading (MeSH) and related entry terms are used to search English literature in PubMed, MEDLINE and CENTRAL databases, respectively. MeSH include: Neuromyelitis optic and Rituximab; entry terms include: NMO Spectrum Disorder, NMO Spectrum Disorders, Neuromyelitis Optica (NMO) Spectrum Disorder, Neuromyelitis Optica Spectrum Disorders, Devic Neuromyelitis Optica, Neuromyelitis Optica, Devic, Devic's Disease, Devic Syndrome, Devic's Neuromyelitis Optica, Neuromyelitis Optica (NMO) Spectrum Disorders, CD20 Antibody, Rituximab CD20 Antibody, Mabthera, IDEC-C2B8 Antibody, GP2013, Rituxan; (note: literature retrieval operators “AND” “OR” “NOT” are used to link MeSH with Entry Terms.) 54 studies were included in this systematic review and 29 studies were included in meta-analysis. The main efficacy indicators were the difference of the expanded disability status scale (EDSS) and annualized relapse rate (ARR) between before and after rituximab treatments. In 29 studies involving 732 patients (643 women, 84 men, 5 with unknown gender), the EDSS and ARR were reduced by an average of −0.57 (95%CI, −0.69 to −0.44), −1.57 (95%CI, −1.78 to −1.35), respectively. Our systematic review and update meta-analysis provide new evidences that RTX can effectively improve disability and reduce ARR ratio." @default.
• W3132348878 created "2021-03-01" @default.
• W3132348878 creator A5038367972 @default.
• W3132348878 creator A5047266765 @default.
• W3132348878 creator A5048186002 @default.
• W3132348878 creator A5068294439 @default.
• W3132348878 date "2021-05-01" @default.
• W3132348878 modified "2023-10-16" @default.
• W3132348878 title "Efficacy of rituximab in the treatment of neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis" @default.
• W3132348878 cites W1522374426 @default.
• W3132348878 cites W1823172479 @default.
• W3132348878 cites W1972241906 @default.
• W3132348878 cites W1994008951 @default.
• W3132348878 cites W1999266868 @default.
• W3132348878 cites W2005486905 @default.
• W3132348878 cites W2014893669 @default.
• W3132348878 cites W2021279859 @default.
• W3132348878 cites W2029012161 @default.
• W3132348878 cites W2029600633 @default.
• W3132348878 cites W2046640562 @default.
• W3132348878 cites W2058748771 @default.
• W3132348878 cites W2082237468 @default.
• W3132348878 cites W2087529564 @default.
• W3132348878 cites W2089363506 @default.
• W3132348878 cites W2106308432 @default.
• W3132348878 cites W2114782321 @default.
• W3132348878 cites W2126930838 @default.
• W3132348878 cites W2130342500 @default.
• W3132348878 cites W2142340239 @default.
• W3132348878 cites W2155049452 @default.
• W3132348878 cites W2156918730 @default.
• W3132348878 cites W2162364743 @default.
• W3132348878 cites W2185400242 @default.
• W3132348878 cites W2242473891 @default.
• W3132348878 cites W2285134363 @default.
• W3132348878 cites W2296419904 @default.
• W3132348878 cites W2330155556 @default.
• W3132348878 cites W2418688327 @default.
• W3132348878 cites W2524675862 @default.
• W3132348878 cites W2570909152 @default.
• W3132348878 cites W2621138762 @default.
• W3132348878 cites W2625404774 @default.
• W3132348878 cites W2747029006 @default.
• W3132348878 cites W2753021216 @default.
• W3132348878 cites W2781286807 @default.
• W3132348878 cites W2790223348 @default.
• W3132348878 cites W2791305328 @default.
• W3132348878 cites W2791654338 @default.
• W3132348878 cites W2809089465 @default.
• W3132348878 cites W2898365847 @default.
• W3132348878 cites W2908825776 @default.
• W3132348878 cites W2911053528 @default.
• W3132348878 cites W2939976904 @default.
• W3132348878 cites W2972221943 @default.
• W3132348878 cites W3000029321 @default.
• W3132348878 cites W3012054652 @default.
• W3132348878 cites W3012285188 @default.
• W3132348878 cites W3012376934 @default.
• W3132348878 cites W3024107893 @default.
• W3132348878 doi "https://doi.org/10.1016/j.msard.2021.102843" @default.
• W3132348878 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33609924" @default.
• W3132348878 hasPublicationYear "2021" @default.
• W3132348878 type Work @default.
• W3132348878 sameAs 3132348878 @default.
• W3132348878 citedByCount "16" @default.
• W3132348878 countsByYear W31323488782021 @default.
• W3132348878 countsByYear W31323488782022 @default.
• W3132348878 countsByYear W31323488782023 @default.
• W3132348878 crossrefType "journal-article" @default.
• W3132348878 hasAuthorship W3132348878A5038367972 @default.
• W3132348878 hasAuthorship W3132348878A5047266765 @default.
• W3132348878 hasAuthorship W3132348878A5048186002 @default.
• W3132348878 hasAuthorship W3132348878A5068294439 @default.
• W3132348878 hasConcept C118552586 @default.
• W3132348878 hasConcept C159654299 @default.
• W3132348878 hasConcept C16005928 @default.
• W3132348878 hasConcept C18031839 @default.
• W3132348878 hasConcept C203014093 @default.
• W3132348878 hasConcept C2777154362 @default.
• W3132348878 hasConcept C2780640218 @default.
• W3132348878 hasConcept C2780653079 @default.
• W3132348878 hasConcept C2780892749 @default.
• W3132348878 hasConcept C2781137167 @default.
• W3132348878 hasConcept C71924100 @default.
• W3132348878 hasConceptScore W3132348878C118552586 @default.
• W3132348878 hasConceptScore W3132348878C159654299 @default.
• W3132348878 hasConceptScore W3132348878C16005928 @default.
• W3132348878 hasConceptScore W3132348878C18031839 @default.
• W3132348878 hasConceptScore W3132348878C203014093 @default.
• W3132348878 hasConceptScore W3132348878C2777154362 @default.
• W3132348878 hasConceptScore W3132348878C2780640218 @default.
• W3132348878 hasConceptScore W3132348878C2780653079 @default.
• W3132348878 hasConceptScore W3132348878C2780892749 @default.
• W3132348878 hasConceptScore W3132348878C2781137167 @default.
• W3132348878 hasConceptScore W3132348878C71924100 @default.
• W3132348878 hasFunder F4320322919 @default.
• W3132348878 hasLocation W31323488781 @default.
• W3132348878 hasOpenAccess W3132348878 @default.

• next